FindTrial
Sign In

gene profiling study for the efficacy of Trastuzumab

gene profiling study for the efficacy of Trastuzumab - gene profiling study for the efficacy of Trastuzumab

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000002325
Enrollment
60
Registered
2009-08-11
Start date
2009-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. stage IV or recurrence breast cancer patients 2. HER2 positive breast cancer patients with IHC or FISH 3. patients with hormone negative or with positive who were resistant to hormone therapy 4. patients with measurable region 5. PS0-2 6. patinets without visceral crisis 7. EF 55%< 8. patinets approved informed consent

Exclusion criteria

Exclusion criteria: 1. patients with brain metastasis 2. patients with massive effusion 3. patinets with sever heart failure and reduced cardiac function caused treatment with trastuzumab 4. patients with pregnancy

Design outcomes

Primary

MeasureTime frame
repeatability investigation—

Countries

Japan

Contacts

Public ContactChikako Shimizu

National Cancer Center breast and medical onoclogy

NCC_IRBoffice@ml.res.ncc.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026